Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease.

PubWeight™: 0.94‹?›

🔗 View Article (PMC 2823416)

Published in J Biol Chem on November 18, 2009

Authors

Guriqbal S Basi1, Hadar Feinberg, Farshid Oshidari, John Anderson, Robin Barbour, Jeanne Baker, Thomas A Comery, Linnea Diep, Davinder Gill, Kelly Johnson-Wood, Amita Goel, Katerina Grantcharova, Mike Lee, Jingzhi Li, Anthony Partridge, Irene Griswold-Prenner, Nicolas Piot, Don Walker, Angela Widom, Menelas N Pangalos, Peter Seubert, J Steven Jacobsen, Dale Schenk, William I Weis

Author Affiliations

1: Elan Pharmaceuticals, Incorporated, South San Francisco, California 94080, USA. guriq.basi@elan.com

Articles citing this

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep (2013) 1.02

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis (2011) 1.00

On the subject of rigor in the study of amyloid β-protein assembly. Alzheimers Res Ther (2013) 0.94

Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res Ther (2014) 0.84

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. Sci Rep (2015) 0.83

Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis (2015) 0.81

Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide. Mol Immunol (2010) 0.80

Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Aβ antibodies induced by multimeric protein antigen (1-11)E2, preserving the Igg1-skewed isotype distribution. PLoS One (2014) 0.79

Flexible antibodies with nonprotein hinges. Proc Jpn Acad Ser B Phys Biol Sci (2011) 0.77

Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes. Biochim Biophys Acta (2016) 0.77

Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice. Nat Commun (2016) 0.75

Alzheimer's amyloid-β A2T variant and its N-terminal peptides inhibit amyloid-β fibrillization and rescue the induced cytotoxicity. PLoS One (2017) 0.75

Alzheimer's disease--a panorama glimpse. Int J Mol Sci (2014) 0.75

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy. J Biol Chem (2017) 0.75

Articles cited by this

Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01

The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88

Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28

PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61

Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci U S A (1988) 35.13

Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18

A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89

A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78

Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51

Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01

Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science (1990) 4.91

Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron (2004) 4.88

Improving biosensor analysis. J Mol Recognit (2000) 4.83

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39

Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods (1991) 4.34

The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27

Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61

Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem (1993) 3.52

The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry (2000) 3.31

Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20

Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58

Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology (2005) 2.58

Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44

Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol (2006) 2.38

Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods (1997) 2.34

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33

Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2005) 2.05

Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01

COMO: a program for combined molecular replacement. Acta Crystallogr D Biol Crystallogr (2001) 1.91

Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.90

Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav (2005) 1.58

Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem (2002) 1.54

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol (2005) 1.51

Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem (2005) 1.40

Isoaspartate formation and neurodegeneration in Alzheimer's disease. Arch Biochem Biophys (2000) 1.27

Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 1.26

Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun (1997) 1.24

Current progress in beta-amyloid immunotherapy. Curr Opin Immunol (2004) 1.18

Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol (2008) 1.17

Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol (2007) 1.04

Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Biotechnology (N Y) (1991) 1.04

Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci (2007) 1.02

Articles by these authors

High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32

Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature (2007) 14.06

Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature (2011) 13.92

GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21

Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature (2011) 9.61

Deconstructing the cadherin-catenin-actin complex. Cell (2005) 8.39

Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell (2005) 7.62

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39

Crystal structure of the µ-opioid receptor bound to a morphinan antagonist. Nature (2012) 6.18

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76

Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature (2011) 5.35

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03

ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75

IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89

Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature (2012) 3.83

Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature (2012) 3.83

Integrin regulation. Curr Opin Cell Biol (2005) 3.80

Structure of the δ-opioid receptor bound to naltrindole. Nature (2012) 3.69

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol (2002) 3.62

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61

Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet (2005) 3.45

Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol (2005) 3.41

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20

Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature (2010) 3.19

The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86

Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu Rev Cell Dev Biol (2007) 2.86

Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat Struct Mol Biol (2004) 2.83

Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun (2003) 2.82

E-cadherin is under constitutive actomyosin-generated tension that is increased at cell-cell contacts upon externally applied stretch. Proc Natl Acad Sci U S A (2012) 2.82

An epithelial tissue in Dictyostelium challenges the traditional origin of metazoan multicellularity. Bioessays (2012) 2.81

Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci (2010) 2.78

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58

Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Biol (2005) 2.57

Conformational changes of p97 during nucleotide hydrolysis determined by small-angle X-Ray scattering. Structure (2005) 2.53

Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49

High-resolution crystal structure of human protease-activated receptor 1. Nature (2012) 2.44

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44

Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle. Nat Struct Biol (2002) 2.38

Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron (2007) 2.38

Structure and biochemistry of cadherins and catenins. Cold Spring Harb Perspect Biol (2009) 2.37

Improved structures of full-length p97, an AAA ATPase: implications for mechanisms of nucleotide-dependent conformational change. Structure (2008) 2.36

Munc18a controls SNARE assembly through its interaction with the syntaxin N-peptide. EMBO J (2008) 2.33

Secondhand smoke in apartment buildings: renter and owner or manager perspectives. Nicotine Tob Res (2007) 2.31

Biochemical and structural definition of the l-afadin- and actin-binding sites of alpha-catenin. J Biol Chem (2002) 2.31

Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci (2008) 2.29

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell (2006) 2.28

Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25

Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem (2007) 2.22

The β-catenin destruction complex. Cold Spring Harb Perspect Biol (2013) 2.22

Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe (2011) 2.20

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19

Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med (2003) 2.18

Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature (2013) 2.14

Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. Mol Cell (2004) 2.13

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2005) 2.05

Thermodynamics of beta-catenin-ligand interactions: the roles of the N- and C-terminal tails in modulating binding affinity. J Biol Chem (2005) 2.04

mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res Mol Brain Res (2002) 1.98

Structures of two intermediate filament-binding fragments of desmoplakin reveal a unique repeat motif structure. Nat Struct Biol (2002) 1.97

Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci (2008) 1.92

ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell (2002) 1.88

Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys (2003) 1.88

Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. PLoS One (2008) 1.86

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.85

A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood (2011) 1.84

The clustering of GABA(A) receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin. J Neurosci (2008) 1.83

Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82

AlphaE-catenin regulates actin dynamics independently of cadherin-mediated cell-cell adhesion. J Cell Biol (2010) 1.81

Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol (2010) 1.81

Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis (2008) 1.77

Effects of dexmedetomidine on propofol and remifentanil infusion rates during total intravenous anesthesia for spine surgery in adolescents. Paediatr Anaesth (2008) 1.74

Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci (2008) 1.70

The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66

Diabetes and driving. Diabetes Care (2012) 1.66